

Correction

Correction: Fan et al. Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease. *Molecules* 2022, 27, 7524

Dongxiao Fan ^{1,2}, Chenshu Liu ^{1,2}, Zhongyu Zhang ^{3,4}, Kan Huang ^{1,2}, Tengyao Wang ^{3,4}, Sifan Chen ^{3,4} and Zilun Li ^{1,2,*}

- ¹ Division of Vascular Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
 - ² National-Guangdong Joint Engineering Laboratory for Diagnosis and Treatment of Vascular Diseases, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
 - ³ Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
 - ⁴ Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
- * Correspondence: lizilun@mail.sysu.edu.cn

Text Correction

- Figure 1 of the original publication [1]: the figure legend “PPAR α : peroxisome proliferator-activated receptor-gamma coactivator-1 α ” should be “PPAR α : peroxisome proliferator-activated receptor α ”.

Original: PPAR α : peroxisome proliferator-activated receptor-gamma coactivator-1 α .

Correction: PPAR α : peroxisome proliferator-activated receptor α .

- The fourth paragraph of Section 2.1 in the original publication, “peroxisome proliferator-activated receptor-gamma coactivator-1 α (PPAR α)” should be “peroxisome proliferator-activated receptor-gamma coactivator-1 α (PGC1 α)”.

Original: peroxisome proliferator-activated receptor-gamma coactivator-1 α (PPAR α).

Correction: peroxisome proliferator-activated receptor-gamma coactivator-1 α (PGC1 α).

- In the final paragraph of Section 2.2, “SIRT1-mediated activation of PPAR α and its coactivator peroxisome proliferator-activated receptor-gamma coactivator-1 α (PGC1 α)” should be “SIRT1-mediated activation of peroxisome proliferator-activated receptor α (PPAR α) and its coactivator PGC1 α ”.

Original: SIRT1-mediated activation of PPAR α and its coactivator peroxisome proliferator-activated receptor-gamma coactivator-1 α (PGC1 α).

Correction: SIRT1-mediated activation of peroxisome proliferator-activated receptor α (PPAR α) and its coactivator PGC1 α .

Reference

1. Fan, D.; Liu, C.; Zhang, Z.; Huang, K.; Wang, T.; Chen, S.; Li, Z. Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease. *Molecules* **2022**, *27*, 7524. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.



Citation: Fan, D.; Liu, C.; Zhang, Z.; Huang, K.; Wang, T.; Chen, S.; Li, Z. Correction: Fan et al. Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease. *Molecules* **2022**, *27*, 7524. *Molecules* **2024**, *29*, 4840. <https://doi.org/10.3390/molecules29204840>

Received: 7 December 2022

Accepted: 11 June 2024

Published: 12 October 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).